drugset / Trial / NCT03789032

Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

NCT03789032

Phase 1 Completed 20 enrolled Akebia Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, fixed sequence, open-label study to evaluate the effect of multiple oral doses of rabeprazole on the pharmacokinetics of a single dose of vadadustat 300 mg in healthy male and female subjects.

Timeline

Start
2018-10-03
Primary completion
2018-11-09
Completion
2018-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 20 mg Oral
Subject Vadadustat Small molecule 300 mg

Indications

No indication recorded.